SCHEMBL3365663

SCHEMBL3365663

C[SiH](C)C(C)(C)COCCOc1ccc(Br)c(F)c1

nearest known ligand 0.37

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
NSD2 O96028 1/20 0.37
NSD3 Q9BZ95 1/20 0.37
SLC6A4 P31645 1/20 0.36
KDM4E B2RXH2 2/20 0.33
MAPK1 P28482 1/20 0.33
TDP1 Q9NUW8 1/20 0.33
MCHR1 Q99705 1/20 0.33
EGFR P00533 1/20 0.33
KDR P35968 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
ALDH1A1 P00352 2/20 0.33
NPC1 O15118 1/20 0.33
MAPT P10636 1/20 0.33
RAB9A P51151 1/20 0.33
HSP90AB1 P08238 1/20 0.32
MAOB P27338 2/20 0.31
RARA P10276 1/20 0.31
RARB P10826 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20521473 0.89 KDM4E (0.33) KDM4EMAPK1TDP1SMN1; SMN2ALDH1A1
SCHEMBL4738422 0.85 SMN1; SMN2 (0.39) KDM4EMAPK1TDP1SMN1; SMN2ALDH1A1
SCHEMBL2474079 0.81 KDM4E (0.49) KDM4ESMN1; SMN2ALDH1A1HSP90AB1MAOB
SCHEMBL1284438 0.78 MAOB (0.45) KDM4ESMN1; SMN2ALDH1A1NPC1MAPT
SCHEMBL7934071 0.77 RARB (0.43) NSD2NSD3SLC6A4KDM4EMAPK1
SCHEMBL21493142 0.76 ALDH1A1 (0.32) SLC6A4ALDH1A1
SCHEMBL12492969 0.76 PDK2 (0.30)
SCHEMBL8226162 0.75 NSD2 (0.44) NSD2NSD3SLC6A4EGFRKDR
SCHEMBL21930755 0.73 KDM4E (0.40) KDM4ETDP1SMN1; SMN2ALDH1A1MAPT
SCHEMBL9931761 0.73 NSD2 (0.45) NSD2NSD3SLC6A4MAPK1EGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1996590-B1 SPIROINDOLINONE DERIVATIVES HOFFMANN LA ROCHE (CH) 2010-10-06 EP disclosed
US-7495007-B2 Spiroindolinone derivatives HOFFMANN-LA ROCHE INC. (US) 2009-02-24 US disclosed
EP-1996590-A1 SPIROINDOLINONE DERIVATIVES F. Hoffmann-la Roche AG (CH) 2008-12-03 EP disclosed
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES HOFFMANN-LA ROCHE INC. 2008-01-10 US disclosed
WO-2007104664-A1 SPIROINDOLINONE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2007-09-20 WO disclosed
US-20070213341-A1 Spiroindolinone derivatives CHEN LI 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009486-A1 SPIROINDOLINONE DERIVATIVES RB1, PKD1, KRAS NSD2 811/4885NSD3 715/4885SLC6A4 3424/4885
US-20070213341-A1 Spiroindolinone derivatives MKI67, PKD1, RCC2 NSD2 1024/4885NSD3 1240/4885SLC6A4 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.